Clinical evidence for a causative link between chronic inflammation and cancer has come from epidemiological studies. These studies reported that inhibiting chronic inflammation in patients with premalignant disease, or who are predisposed to cancer development, reduces cancer risk and/or cancer recurrence (for review see Thun et al., 2002) . Molecular mechanisms linking inflammation and development of epithelial cancer have only recently been provided by utilization of sophisticated in vivo molecular methodologies, in combination with immune-competent mouse models of multistage carcinogenesis (reviewed in de Visser et al., 2006 and Karin, 2006) . These have revealed the significance of the transcription factor nuclear factor κB (NFκB) and its activating IκB kinases (IKKα and β) in cancer progression via their ability to differentially regulate cell survival and production of proinflammatory cytokines. According to Luo et al. (2007) , as recently reported in Nature, IKKα also promotes metastasis.
Using a transgenic mouse model of prostate cancer in which the SV40 large T antigen is selectively expressed in prostate epithelium (TRAMP mice), Luo and colleagues (2007) have identified IKKα as a key mediator of the interplay between inflammation and metastasis in prostate cancer. To address the functional significance of IKKα, TRAMP mice were crossed with mice harboring an inactive IKKα (IKKα AA/AA /TRAMP). In these mice both the onset of tumors and mortality were delayed, whereas the histopathology and size of the primary tumor was not changed compared to mice with wild-type IKKα. Instead, IKKα AA/AA /TRAMP mice developed significantly fewer metastases in distant organs. This effect was associated with sustained expression levels of the metastasis suppressor maspin (mammary serine protease inhibitor).
Maspin was first identified as a putative suppressor of metastasis by virtue of its high level of expression in normal mammary epithelial cells as compared to its greatly reduced or absent expression in malignant cells (reviewed in Sheng, 2004) . Due to its structural homology to serine protease inhibitors (serpins), maspin was initially thought to regulate metastasis via inhibition of serine proteases involved in regulating cell-cell and/or cell-extracellular matrix interactions. However, it was later determined that maspin did not inhibit trypsin-like serine proteases, providing compelling evidence that maspin, unlike other serpins, was not a classical serine protease inhibitor. More recent investigations revealed that maspin regulates metastasis, in part, by altering integrin profiles associated with increased cellular adherence to fibronectin, thus reducing ability of cells to move through fibronectin matrices. Although maspin displays antimetastatic properties during mammary and prostate cancer development, its expression is maintained during ovarian, lung, and pancreatic carcinogenesis, indicating that maspin-regulated metastatic potential is tissue specific.
Loss of maspin expression during tumor progression was demonstrated to result, in part, from absent Ets and Ap1 transactivation in combination with epigenetic silencing by methylation (Sato et al., 2004 The development of solid tumors is regulated by dynamic interactions between evolving neoplastic cells and their microenvironment. Luo et al. (2007) recently demonstrated that tumorinfiltrating immune cells expressing RANKL induce activation and nuclear localization of IKKα in prostatic epithelial tumor cells. This leads to repression of maspin, a critical suppressor of metastasis, and thus commits malignant prostatic epithelial cells to a metastatic fate.
soluble RANKL (sRANKL) (Zhang et al., 2001) ; RANKL is also expressed by lymphoid and myeloid cells; thus, as immune cells are recruited to sites of neoplastic growth, local levels of RANKL increase. The observations presented by Luo et al. (2007) demonstrate that in primary prostate cancers, it is indeed infiltrating T lymphocytes and macrophages that express RANKL. Whether these infiltrating cells express soluble RANKL or how membrane-associated RANKL is activated remain undetermined.
The ability of macrophages to promote tumorigenesis has been previously reported using a mouse model of mammary carcinogenesis, in which infiltration of macrophages into premalignant mammary tissue is associated with primary tumor progression (Lin et al., 2006 and references therein). Depletion of or failure to recruit macrophages into neoplastic tissue does not significantly alter hallmarks of premalignancy but instead significantly delays development of invasive carcinomas (likely through regulation of angiogenesis) and reduces the formation of pulmonary metastasis (Lin et al., 2006) . This indicates that molecules secreted by tissue macrophages, in addition to enhancing primary tumor development via pro-angiogenic mechanisms, also mediate metastatic progression of mammary tumors. Studies by Luo et al. (2007) now provide a new mechanism for the promotion of metastasis in which recruited macrophages secrete the proinflammatory cytokine RANKL. This binds RANK and leads to the phosphorylation of IKKα to induce repression of maspin in malignant epithelial cells, therefore enhancing their metastasis (Figure 1) . Interestingly, IKKβ does not possess similar ability to promote metastasis in prostate cancer. This is surprising given that it confers survival signals to enterocytes enabling them to evade apoptotic elimination. IKKβ also induces the production of proinflammatory cytokines by myeloid cells that act as paracrine growth factors for the premalignant enterocytes (reviewed in Karin, 2006) . Taken together, these reports highlight the significance of IKK family members as important regulators of not only cancer initiation and promotion but now also metastasis and offer insights into potential new therapeutic targets for treatment of metastatic disease, namely RANKL/ RANK, IKKα, and maspin.
Maspin is an intriguing candidate for new therapies. Indeed, demethylation of the maspin promoter enabling maspin re-expression in malignant cells could represent a viable approach to inhibit metastasis of malignant prostatic epithelial cells and/or stabilize primary disease. Reactivation of maspin expression could be achieved by use of DNA methylation inhibitors such as 5-aza-2′-deoxycytidine or inhibitors of DNA methyltransferase, including specific DNA methyltransferase hairpin antagonists. Alternatively, because these agents lack specificity, RANKL/RANK or IKKα antagonists could prove useful as they might not only diminish prostate cancer metastasis but would also reduce the bone-degrading activity of metastatic prostate cancer cells that is associated with RANKL signaling. It is interesting to speculate that the efficacy of pyrophosphate analogs, such as bisphosphonates, known to reduce osteolysis associated with prostate cancer (Clezardin et al., 2005) , may be due in part to regulating RANKL/ RANK, IKKα, or maspin bioactivity in malignant tumor cells and/or in infiltrating immune cells. Thus, taken together, identification of this important new pathway by Luo et al. (2007) offers insight into how immune cells affect metastasis and reveals several new potential targets for anticancer therapy.
figure 1. IKKα and Maspin in Prostate Cancer Metastasis
The metastasis suppressor gene maspin is highly expressed in early prostate tumor cells. Following infiltration of RANKL-producing immune cells, RANK phosphorylates and activates IKKα, inducing its nuclear translocation and interaction with the maspin promoter causing its transient repression. This gene is then silenced by methylation, committing prostate cancers to a metastatic fate. Activation of RANK on prostate cancer cells requires either close contact with RANKLexpressing immune cells, cleavage of the RANKL extracellular domain by proteases such as MMP-7, or alternatively, immune cell expression of a secreted form of RANKL.
